当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
TRUMENBA, Meningococcal Group B Vaccine
申请企业
Wyeth Pharmaceuticals LLC
药品名称
TRUMENBA, Meningococcal Group B Vaccine
承诺描述
A deferred pediatric study under PREA to evaluate the safety and immunogenicity of a 2-dose regimen (0 and 6 months) of Trumenba in children 1 year to less than 10 years of age for the prevention of invasive group B meningococcal disease
承诺状态描述
The final protocol due date had passed with no protocol received.
报告接收日期
2020/12/18 0:00:00